NCT06186622 A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants Status COMPLETED Phase PHASE1
NCT06109311 A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor Status COMPLETED Phase PHASE3
NCT06045221 A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin Status COMPLETED Phase PHASE3
NCT06010004 A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Status COMPLETED Phase PHASE3
NCT05971940 A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone Status COMPLETED Phase PHASE3
NCT05931380 A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease Status COMPLETED Phase PHASE3
NCT05872620 A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes Status COMPLETED Phase PHASE3
NCT05869903 A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk Status COMPLETED Phase PHASE3